

References

1. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. *Drug Saf* 2009; 32(1):19-31.
2. Murri N. Medication management: Strategies to maximize patient safety. *Drug Therapy Topics* 2003; 32(3):11-14.
3. Cardinal Health, Inc. Reducing the human and economic costs of drug therapy complications: responding to the medication safety issue. Revised edition, published 5/00.
www.cardinal.com/content/industrytopics/WhitePaper_ADE_PDF.pdf (last accessed 09/17/09).
4. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. *JAMA* 1997; 277(4):301-306.
5. Kimmel KC, Sensmeier J. White paper: A Technological approach to enhancing patient safety. Healthcare information and Management Systems Society 2002.
www.himss.org/content/files/whitepapers/patient_safety.pdf (last accessed 09/17/09).
6. ADE Prevention Study Group. Incidence of adverse drug events and potential adverse drug events: implications for prevention. *JAMA* 1995; 274(1):29-34.
7. Pezalla E. Preventing adverse drug reactions in the general public. *Manag Care Interface* 2005; 18(10):49-52.
8. ADE Prevention Study Group. The costs of adverse drug events in hospitalized patients. *JAMA* 1997; 277(4):307-311.
9. Committee on Quality of Health Care in America, Institute of Medicine. Priority areas for national action: transforming health care quality. National Academy Press 2003.
www.nap.edu/catalog/10593.html (last accessed 09/17/09).
10. Evans RS, Pestotnik SL, Classen DC, et al. Prevention of adverse drug events through computerized surveillance. *Proc Annu Symp Comput Appl Med Care* 1992; 437-441.